Rigrodsky & Long, P.A. Announces Investigation Of MAP Pharmaceuticals, Inc. Buyout

  Rigrodsky & Long, P.A. Announces Investigation Of MAP Pharmaceuticals, Inc.

Business Wire

WILMINGTON, Del. -- January 24, 2013

Rigrodsky & Long, P.A. announces that it is investigating potential legal
claims against the board of directors of MAP Pharmaceuticals, Inc. (“MAP” or
the “Company”) (NASDAQ GS: MAPP) regarding possible breaches of fiduciary
duties and other violations of law related to the Company’s entry into an
agreement to be acquired by Allergan, Inc. (“Allergan”) (NYSE: AGN) in a
transaction valued at approximately $958 million, on a fully-diluted basis.

Click here to learn more:

Under the terms of the proposal, public shareholders of MAP will receive
$25.00 per share in cash for each share of MAP they own.

The investigation concerns whether MAP’s board of directors failed to
adequately shop the Company and obtain the best possible value for MAP’s
shareholders before entering into an agreement with Allergan.

If you own the common stock of MAP and purchased your shares before January
22, 2013, if you have information or would like to learn more about these
claims, or if you wish to discuss these matters or have any questions
concerning this announcement or your rights or interests with respect to these
matters, please contact Peter Allocco at Rigrodsky & Long, P.A., 825 East Gate
Boulevard, Suite 300, Garden City, New York 11530 toll free at (888) 969-4242,
by e-mail to info@rigrodskylong.com, or at:

Rigrodsky & Long, P.A., with offices in Wilmington, Delaware and Garden City,
New York, regularly prosecutes securities class, derivative and direct
actions, shareholder rights litigation and corporate governance litigation, on
behalf of shareholders in states and federal courts throughout the United

Attorney advertising. Prior results do not guarantee a similar outcome.


Rigrodsky & Long, P.A.
Peter Allocco
Fax: 302-654-7530
Press spacebar to pause and continue. Press esc to stop.